Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Radiation Therapy followed by prostatectomy Clear all
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

NCT07182279
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Brachytherapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

NCT00002874
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, radiation therapy, placebo
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Male only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2022
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 4, 2026, 1:24 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NCT03070886
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide
Drug · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
311
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Withdrawn Phase 1 Interventional

Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer

NCT01163448
View directory record Official record
Conditions
Prostate Cancer
Interventions
High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Results available

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

NCT03388619
View directory record Official record
Conditions
Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate, Prostatic Cancer
Interventions
Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan, 18F-NaF PET Imaging, CT, mpMRI, ADT
Radiation · Diagnostic Test · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Not applicable Interventional Results available

CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation

NCT03657108
View directory record Official record
Conditions
Prostate Cancer
Interventions
Civasheet 60 Gy, Civasheet 75 Gy, Adjuvant external beam radiation therapy
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 4, 2026, 1:24 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Low Intensity Shockwave Therapy for Erectile Dysfunction

NCT04434352
View directory record Official record
Conditions
Erectile Dysfunction, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Radiation Therapy, Erectile Dysfunction Due to General Medical Condition, Erectile Dysfunction Due to Arterial Insufficiency
Interventions
Storz Duolith Low-Intensity Shockwave Therapy
Device
Lead sponsor
University of Virginia
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

Preoperative Radiation Therapy for High Risk Prostate Cancer

NCT01041326
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, Radical Prostatectomy
Radiation · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Not applicable Interventional

Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

NCT00969111
View directory record Official record
Conditions
Prostate Cancer
Interventions
IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Proton (prostate bed) to 70.2 CGE, IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Proton to 66.6 CGE
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2050
U.S. locations
6
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Active, not recruiting Phase 1 Interventional

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

NCT06105918
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy, Flotufolastat F-18, Lutetium Lu 177 PSMA-10.1, Positron Emission Tomography, Single Photon Emission Computed Tomography
Procedure · Radiation · Other + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer

NCT00223665
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Leuprolide Acetate
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Phase 2 Interventional

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

NCT06636682
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
Interventions
FK-PC101, Standard of Care (SOC)
Biological
Lead sponsor
Cellvax Therapeutics Inc
Industry
Eligibility
Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Gahanna, Ohio • Myrtle Beach, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

NCT01548807
View directory record Official record
Conditions
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Interventions
Everolimus (RAD001)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

NCT02203695
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Enzalutamide, SRT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Lafayette, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

NCT00551525
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiotherapy, Samarium 153
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
29
States / cities
Phoenix, Arizona • Auburn, California • Cameron Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Completed No phase listed Observational Results available

Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for Treatment

NCT04890314
View directory record Official record
Conditions
Prostate Cancer
Interventions
Patient-reported questionnaire
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
1,953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Kansas City, Kansas • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Defining Recurrent Disease With Axumin™

NCT03996993
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Casodex, Axumin, Salvage Radiation, Axumin
Drug · Radiation
Lead sponsor
Cancer Center of Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

NCT02572284
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), Prostatectomy, Quality of Life Questionnaires
Radiation · Procedure · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer

NCT00348816
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, prednisone, Radical prostatectomy, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Genomics in Michigan Impacting Observation or Radiation

NCT02783950
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher Prostate Cancer Classifier
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
13
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2Phase 3 Interventional

Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer

NCT00136487
View directory record Official record
Conditions
Prostate Cancer
Interventions
Celecoxib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
9
States / cities
Hartford, Connecticut • Boston, Massachusetts • Concord, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 4, 2026, 1:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations for Radiation Oncologists

NCT02034812
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher Questionnaire
Other
Lead sponsor
GenomeDx Biosciences Corp
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

NCT03311555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Androgen deprivation, Salvage radiation therapy, Docetaxel
Drug · Radiation
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 4, 2026, 1:24 PM EDT